002880 卫光生物
已收盘 05-15 15:00:00
资讯
新帖
简况
卫光生物（002880）披露向特定对象发行A股股票募集说明书（注册稿），5月13日股价下跌1.7%
证券之星 · 05-13
卫光生物（002880）披露向特定对象发行A股股票募集说明书（注册稿），5月13日股价下跌1.7%
股市必读：卫光生物（002880）4月30日董秘有最新回复
证券之星 · 05-06
股市必读：卫光生物（002880）4月30日董秘有最新回复
每周股票复盘：卫光生物（002880）2026年一季度净利降29.21%
证券之星 · 05-03
每周股票复盘：卫光生物（002880）2026年一季度净利降29.21%
卫光生物：公司把握CGT产业发展机遇
证券之星 · 04-30
卫光生物：公司把握CGT产业发展机遇
卫光生物：公司经营情况正常
证券之星 · 04-30
卫光生物：公司经营情况正常
卫光生物：血液制品中的罕见病药物仍适用3%简易征收
证券之星 · 04-30
卫光生物：血液制品中的罕见病药物仍适用3%简易征收
卫光生物（002880）2026年一季报简析：净利润同比下降29.21%，应收账款上升
证券之星 · 04-28
卫光生物（002880）2026年一季报简析：净利润同比下降29.21%，应收账款上升
卫光生物（002880）披露2026年一季度报告，4月27日股价下跌0.46%
证券之星 · 04-27
卫光生物（002880）披露2026年一季度报告，4月27日股价下跌0.46%
图解卫光生物年报：第四季度单季净利润同比增长24.92%
证券之星 · 04-26
图解卫光生物年报：第四季度单季净利润同比增长24.92%
卫光生物最新公告：向特定对象发行股票申请获深交所审核通过
证券之星 · 04-09
卫光生物最新公告：向特定对象发行股票申请获深交所审核通过
卫光生物最新公告：皮下注射人免疫球蛋白获准开展临床试验
证券之星 · 03-24
卫光生物最新公告：皮下注射人免疫球蛋白获准开展临床试验
股市必读：卫光生物（002880）3月23日收盘跌8.59%，主力净流入301.24万元
证券之星 · 03-24
股市必读：卫光生物（002880）3月23日收盘跌8.59%，主力净流入301.24万元
卫光生物最新公告：收到人凝血因子Ⅸ境内生产药品注册临床试验受理通知书
证券之星 · 03-06
卫光生物最新公告：收到人凝血因子Ⅸ境内生产药品注册临床试验受理通知书
卫光生物：持续提升公司盈利能力和内在价值
证券之星 · 02-11
卫光生物：持续提升公司盈利能力和内在价值
2月5日卫光生物（002880）龙虎榜数据：机构净买入462.76万元，北向资金净买入1038.21万元
证券之星 · 02-05
2月5日卫光生物（002880）龙虎榜数据：机构净买入462.76万元，北向资金净买入1038.21万元
卫光生物（002880）披露拟设立羲和生命科技公司建设细胞与基因治疗公共服务平台，2月5日股价下跌3.32%
中金财经 · 02-05
卫光生物（002880）披露拟设立羲和生命科技公司建设细胞与基因治疗公共服务平台，2月5日股价下跌3.32%
异动快报：卫光生物（002880）2月5日13点11分触及涨停板
证券之星 · 02-05
异动快报：卫光生物（002880）2月5日13点11分触及涨停板
卫光生物最新公告：拟投资4000万元参与设立项目公司建设细胞与基因治疗市场化公共服务平台
证券之星 · 02-04
卫光生物最新公告：拟投资4000万元参与设立项目公司建设细胞与基因治疗市场化公共服务平台
股市必读：卫光生物（002880）1月30日收盘跌停，主力净流出4075.36万元
证券之星 · 02-02
股市必读：卫光生物（002880）1月30日收盘跌停，主力净流出4075.36万元
异动快报：卫光生物（002880）1月30日14点49分触及跌停板
证券之星 · 01-30
异动快报：卫光生物（002880）1月30日14点49分触及跌停板
公司概况
公司名称：
深圳市卫光生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-06-16
主营业务：
深圳市卫光生物制品股份有限公司的主营业务是血液制品。公司的主要产品是人血白蛋白、静注人免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血因子Ⅷ、人凝血酶原复合物。
发行价格：
25.11
{"stockData":{"symbol":"002880","market":"SZ","secType":"STK","nameCN":"卫光生物","latestPrice":25.76,"timestamp":1778828610000,"preClose":25.61,"halted":0,"volume":1024720,"delay":0,"changeRate":0.0059,"floatShares":227000000,"shares":227000000,"eps":1.0297,"marketStatus":"已收盘","change":0.15,"latestTime":"05-15 15:00:00","open":25.58,"high":25.88,"low":25.48,"amount":26275400,"amplitude":0.0156,"askPrice":25.77,"askSize":25,"bidPrice":25.76,"bidSize":121,"shortable":0,"etf":0,"ttmEps":1.0297,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":25.61,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":28.17,"lowLimit":23.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":226800000,"isCdr":false,"pbRate":2.38,"roa":"--","peRate":25.016995,"roe":"1.28%","epsLYR":1.0861,"committee":0.480249,"marketValue":5842000000,"turnoverRate":0.0045,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-18。","floatMarketCap":5842000000},"requestUrl":"/m/hq/s/002880/wiki","defaultTab":"wiki","newsList":[{"id":"2635858247","title":"卫光生物（002880）披露向特定对象发行A股股票募集说明书（注册稿），5月13日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635858247","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635858247?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:36","pubTimestamp":1778668606,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，卫光生物报收于26.06元，较前一交易日下跌1.7%，最新总市值为59.1亿元。该股当日开盘26.56元，最高26.59元，最低26.0元，成交额达5424.11万元，换手率为0.91%。公司于近日披露《深圳市卫光生物制品股份有限公司向特定对象发行A股股票募集说明书（注册稿）》。公告显示，公司拟向特定对象发行A股股票，募集资金总额不超过15亿元，用于建设年处理血浆1,200吨的智能产业基地项目及补充流动资金。本次发行不会导致公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300034800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","159982","399300","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924252","title":"股市必读：卫光生物（002880）4月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633924252?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:43","pubTimestamp":1778013789,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，卫光生物报收于25.71元，下跌0.12%，换手率0.52%，成交量1.17万手，成交额3009.51万元。依据国家增值税有关最新政策规定，血液制品中的罕见病药物仍适用3%简易征收，其他血液制品不再适用3%简易征收。本次增值税征收调整对血液制品行业有一定影响。公司的实际控制人是深圳市光明区国有资产监督管理局。公司目前暂未开展创新药的研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632575677","title":"每周股票复盘：卫光生物（002880）2026年一季度净利降29.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632575677","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632575677?lang=zh_cn&edition=full","pubTime":"2026-05-03 05:33","pubTimestamp":1777757591,"startTime":"0","endTime":"0","summary":"关于2025年度日常关联交易执行情况及预计2026年度日常关联交易的议案获董事会审议通过。本次计提导致2025年度利润总额减少2,504.41万元，归属于上市公司所有者权益减少1,970.22万元。业绩披露要点2026年一季度营业收入为221,871,720.94元，同比减少1.39%；归属于上市公司股东的净利润为30,982,974.04元，同比减少29.21%；经营活动产生的现金流量净额为-117,591,027.34元，同比减少653.82%。2025年度实现营业收入1,266,661,537.66元，归属于母公司股东的净利润为246,320,739.85元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631168901","title":"卫光生物：公司把握CGT产业发展机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2631168901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631168901?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:12","pubTimestamp":1777540328,"startTime":"0","endTime":"0","summary":"公司于2026年2月披露了与合作方共同出资建设深圳市细胞与基因治疗市场化公共服务平台事项，公司把握CGT产业发展机遇，精准对接国家战略发展需求，填补区域空白，解决CGT产业化的“卡脖子”问题。截至目前，合资公司已经成立，公司管理层将继续保持锐意进取的精神，积极把握行业政策机会，稳步推进公司在CGT领域的重要探索。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631890156","title":"卫光生物：公司经营情况正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2631890156","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631890156?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:09","pubTimestamp":1777540144,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物(002880)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的基本面是否正常？卫光生物回复：尊敬的投资者朋友，您好！感谢您对公司的关心和关注。公司经营情况正常，具体经营信息请参阅披露于巨潮资讯网的《2025年年度报告》和《2026年第一季度报告》相关内容。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631798689","title":"卫光生物：血液制品中的罕见病药物仍适用3%简易征收","url":"https://stock-news.laohu8.com/highlight/detail?id=2631798689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631798689?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:06","pubTimestamp":1777539975,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的公司领导，请问公司增值税征收方式是否从 3% 简易征收调整为 13% 一般征收？依据国家增值税有关最新政策规定，血液制品中的罕见病药物仍适用3%简易征收，其他血液制品不再适用3%简易征收。公司将通过持续优化供应链管理和进项抵扣管理等经营举措，降低因政策变化给公司带来的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","002880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630346810","title":"卫光生物（002880）2026年一季报简析：净利润同比下降29.21%，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2630346810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630346810?lang=zh_cn&edition=full","pubTime":"2026-04-28 06:52","pubTimestamp":1777330376,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期卫光生物发布2026年一季报。截至本报告期末，公司营业总收入2.22亿元，同比下降1.39%，归母净利润3098.3万元，同比下降29.21%。本报告期卫光生物应收账款上升，应收账款同比增幅达210.13%。去年的净利率为19.4%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800022520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630053360","title":"卫光生物（002880）披露2026年一季度报告，4月27日股价下跌0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630053360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630053360?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:44","pubTimestamp":1777286688,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，卫光生物报收于25.94元，较前一交易日下跌0.46%，最新总市值为58.83亿元。该股当日开盘25.89元，最高25.94元，最低25.26元，成交额达3993.8万元，换手率为0.69%。公司于2026年4月27日披露《2026年一季度报告》。截至2026年3月31日，公司总资产为3,667,306,359.89元，较上年度末减少1.95%；归属于上市公司股东的所有者权益为2,443,369,045.03元，较上年度末增长1.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700035299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630381763","title":"图解卫光生物年报：第四季度单季净利润同比增长24.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630381763","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630381763?lang=zh_cn&edition=full","pubTime":"2026-04-26 17:06","pubTimestamp":1777194367,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物2025年年报显示，当年度公司主营收入12.67亿元，同比上升5.28%；归母净利润2.46亿元，同比下降2.84%；扣非净利润2.39亿元，同比下降9.44%；其中2025年第四季度，公司单季度主营收入4.76亿元，同比上升36.29%；单季度归母净利润8846.02万元，同比上升24.92%；单季度扣非净利润8319.65万元，同比下降2.71%；负债率34.62%，投资收益377.34万元，财务费用2058.82万元，毛利率39.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600010493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626461184","title":"卫光生物最新公告：向特定对象发行股票申请获深交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2626461184","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626461184?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:11","pubTimestamp":1775736660,"startTime":"0","endTime":"0","summary":"卫光生物公告称，公司于4月9日收到深交所上市审核中心出具的《关于深圳市卫光生物制品股份有限公司申请向特定对象发行股票的审核中心意见告知函》。深交所发行上市审核机构对公司向特定对象发行股票的申请文件进行了审核，认为公司符合发行条件、上市条件和信息披露要求。后续深交所将按规定报证监会履行相关注册程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900034717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306815","title":"卫光生物最新公告：皮下注射人免疫球蛋白获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306815","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621306815?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:29","pubTimestamp":1774344590,"startTime":"0","endTime":"0","summary":"卫光生物(002880.SZ)公告称，公司近日收到国家药监局下发的《药物临床试验批准通知书》，同意其“皮下注射人免疫球蛋白”开展用于治疗原发性免疫缺陷病(PID)的临床试验。该产品目前国内尚无同类皮下给药产品获批，海外已有HIZENTRA、CUVITRU、XEMBIFY等上市。公司需在3年内启动临床试验，否则通知书将失效。药品研发周期长、环节多，临床进度及结果存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400029665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","002880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081461","title":"股市必读：卫光生物（002880）3月23日收盘跌8.59%，主力净流入301.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081461","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621081461?lang=zh_cn&edition=full","pubTime":"2026-03-24 03:59","pubTimestamp":1774295973,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，卫光生物报收于26.19元，下跌8.59%，换手率2.05%，成交量4.65万手，成交额1.25亿元。来自资金流向：3月23日主力资金净流入301.24万元，与前10日主力持续净流出形成反差。交易信息汇总股价提醒3月23日卫光生物收盘报26.19元，跌8.59%，当日成交464.84万元。根据收盘数据统计，该股已连续6日下跌。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617689126","title":"卫光生物最新公告：收到人凝血因子Ⅸ境内生产药品注册临床试验受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2617689126","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617689126?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:50","pubTimestamp":1772790655,"startTime":"0","endTime":"0","summary":"卫光生物(002880.SZ)公告称，公司近日收到国家药品监督管理局签发的人凝血因子Ⅸ境内生产药品注册临床试验申请《受理通知书》。人凝血因子Ⅸ主要用于B型血友病患者的出血治疗，通过补充患者体内缺乏的凝血因子Ⅸ，帮助血液凝固，控制或预防出血。目前国内拥有人凝血因子Ⅸ上市批件的企业包括山东泰邦生物制品有限公司、远大蜀阳生命科学（成都）有限公司等。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600029385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002880","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610986079","title":"卫光生物：持续提升公司盈利能力和内在价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2610986079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610986079?lang=zh_cn&edition=full","pubTime":"2026-02-11 15:27","pubTimestamp":1770794827,"startTime":"0","endTime":"0","summary":"公司非常重视市值管理，自上市以来，公司持续通过实施现金分红、送红股等多种方式回报全体股东，不断提升信息披露工作质量，以深交所信息披露评级“六连A”的规范运作和治理水平向广大投资者传递公司价值。在持续提升公司盈利能力和内在价值、夯实血液制品主业的同时，公司还积极布局细胞与基因治疗等生物医药前沿领域，培育新的利润增长点，增强公司差异化竞争优势，提升公司的长期市值表现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100018965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609378824","title":"2月5日卫光生物（002880）龙虎榜数据：机构净买入462.76万元，北向资金净买入1038.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609378824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609378824?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:31","pubTimestamp":1770283914,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年2月5日公布的交易公开信息显示，卫光生物因日振幅值达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年2月5日收盘，卫光生物报收于29.7元，下跌3.32%，换手率11.23%，成交量25.48万手，成交额8.15亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入462.76万元，北向资金合计净买入1038.21万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500028340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","002880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609788873","title":"卫光生物（002880）披露拟设立羲和生命科技公司建设细胞与基因治疗公共服务平台，2月5日股价下跌3.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609788873","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609788873?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:31","pubTimestamp":1770283872,"startTime":"0","endTime":"0","summary":"近日，卫光生物披露《关于对外投资的自愿性披露公告》。公告显示，公司拟与深业生物、深圳细胞谷及赛桥生物共同出资设立深圳市羲和生命科技有限责任公司，建设深圳市细胞与基因治疗市场化公共服务平台。董事会已审议通过该投资事项，无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260205/32001181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0046","BK0239","002880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609478473","title":"异动快报：卫光生物（002880）2月5日13点11分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2609478473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609478473?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:15","pubTimestamp":1770268524,"startTime":"0","endTime":"0","summary":"证券之星2月5日盘中消息，13点11分卫光生物（002880）触及涨停板。其所属行业生物制品目前下跌。领涨股为卫光生物。该股为血制品，合成生物，医药概念热股，当日血制品概念上涨1.64%。2月4日的资金流向数据方面，主力资金净流出1457.34万元，占总成交额4.55%，游资资金净流出2379.91万元，占总成交额7.44%，散户资金净流入3837.25万元，占总成交额11.99%。近5日资金流向一览见下表：卫光生物主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500018506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608366070","title":"卫光生物最新公告：拟投资4000万元参与设立项目公司建设细胞与基因治疗市场化公共服务平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2608366070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608366070?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:11","pubTimestamp":1770207078,"startTime":"0","endTime":"0","summary":"卫光生物(002880.SZ)公告称，公司拟与深圳市深业生物医药产业发展有限公司、深圳细胞谷生物医药有限公司及深圳赛桥生物创新技术有限公司共同出资设立深圳市羲和生命科技有限责任公司，建设深圳市细胞与基因治疗市场化公共服务平台。公司认缴出资4000万元，占项目公司股权比例为40%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400037823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608685885","title":"股市必读：卫光生物（002880）1月30日收盘跌停，主力净流出4075.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608685885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608685885?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:16","pubTimestamp":1769966173,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，卫光生物报收于27.06元，下跌10.01%，跌停，换手率4.87%，成交量11.04万手，成交额3.1亿元。交易信息汇总股价提醒1月30日卫光生物收盘报27.06元，跌停，当日成交1103.78万元。前10个交易日资金流向情况：主力资金累计净流出303.68万元，股价累计上涨3.68%。资金流向1月30日主力资金净流出4075.36万元；游资资金净流入2723.56万元；散户资金净流入1351.8万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607084096","title":"异动快报：卫光生物（002880）1月30日14点49分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607084096?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:50","pubTimestamp":1769755832,"startTime":"0","endTime":"0","summary":"证券之星1月30日盘中消息，14点49分卫光生物（002880）触及跌停板。其所属行业生物制品目前下跌。领涨股为*ST四环。该股为深圳本地股，合成生物，医药概念热股。1月29日的资金流向数据方面，主力资金净流入1249.71万元，占总成交额4.7%，游资资金净流出2350.38万元，占总成交额8.83%，散户资金净流入1100.68万元，占总成交额4.14%。近5日资金流向一览见下表：卫光生物主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000019945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002880","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778931264794,"stockEarnings":[{"period":"1week","weight":-0.0008},{"period":"1month","weight":-0.047},{"period":"3month","weight":-0.165},{"period":"6month","weight":-0.0823},{"period":"1year","weight":-0.0726},{"period":"ytd","weight":0.0102}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳市卫光生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15508人(较上一季度增加28.15%)","perCapita":"14624股","listingDate":"2017-06-16","address":"广东省深圳市光明区光明街道碧眼社区光侨大道3402号办公楼一层","registeredCapital":"22680万元","survey":" 深圳市卫光生物制品股份有限公司的主营业务是血液制品。公司的主要产品是人血白蛋白、静注人免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血因子Ⅷ、人凝血酶原复合物。","listedPrice":25.11},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"卫光生物(002880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供卫光生物(002880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"卫光生物,002880,卫光生物股票,卫光生物股票老虎,卫光生物股票老虎国际,卫光生物行情,卫光生物股票行情,卫光生物股价,卫光生物股市,卫光生物股票价格,卫光生物股票交易,卫光生物股票购买,卫光生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"卫光生物(002880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供卫光生物(002880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}